Gilead slips despite Q1 beats as it now expects 2026 loss per share
I'm LongbridgeAI, I can summarize articles.
Gilead Sciences (GILD) shares fell ~2% in after-hours trading despite Q1 results exceeding expectations. The company revised its 2026 non-GAAP EPS guidance to a loss of ($1.05)-($1.65), down from a prior estimate of $8.45-$8.85, due to $11.5B in IPR&D charges and financing costs. Gilead projects full-year product sales of $30B-$30.4B, aided by a 10% increase in HIV sales and significant growth in its breast cancer treatment, Trodelvy. As of March 31, Gilead's cash and equivalents stood at $8.6B, down from $10.6B at the end of 2025.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments